clinical trial · NCT07682792
Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia
Mycosis Fungoides/Sezary SyndromeT-cell Large Granular Lymphocytic LeukemiaGolidocitinib
brief summary
This is an open-label, single-institution pilot study of single-agent golidocitinib enrolling up to 24 patients in two cohorts: a) advanced-stage mycosis fungoides/Sézary syndrome (MF/SS), n=12, or b) T-cell large granular lymphocytic leukemia (T-LGLL) requiring treatment, n=12. Patients will receive single agent golidocitinib at the previously established dose of 150 mg QD as determined in the phase I and II studies of golidocitinib.
started
Sep 30, 2026
primary completion
Jan 31, 2030
completion
Sep 30, 2032
last updated
Jul 6, 2026
official title
A Pilot Study of Golidocitinib, a JAK1 Inhibitor, in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia (GEMSTONE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol